Monarch Disease Ontology release 2018-06-29sonu — 2018-06-29 — 2018. ↑ Diagnosis of Polycystic Ovarian Syndrome: The Rotterdam Criteria Are Premature // Journal of Clinical Endocrinology & Metabolism : journal. — 2006. — March (vol. 91, no. 3). — P. 781—785. — doi:10.1210/jc.2005-2153. — . ↑ Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. // Minerva ginecologica : journal. — 2004. — February (vol. 56, no. 1). — P. 1—6. — . ↑ Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome // Best Practice & Research Clinical Obstetrics & Gynaecology : journal. — 2004. — October (vol. 18, no. 5). — P. 671—683. — doi:10.1016/j.bpobgyn.2004.05.001. — . ↑ Diagnosis of Hyperandrogenism in Female Adolescents. . Armenian Health Network, Health.am (Sep 21 2006). ↑ The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome // Fertil. Steril. : journal. — 2010. — April (vol. 93, no. 6). — P. 1864—1869. — doi:10.1016/j.fertnstert.2008.12.024. — . ↑ Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome // Fertil. Steril. : journal. — 2002. — May (vol. 77, no. 5). — P. 936—944. — . ↑ Role of opioid tone in the pathophysiology of hyperinsulinemia and insulin resistance in polycystic ovarian disease // Metab. Clin. Exp. : journal. — 1998. — February (vol. 47, no. 2). — P. 158—162. — . ↑ [Study of dopamine effect on neuroendocrine disorders during polycystic-ovary syndrome using the method of enzyme-linked immunosorbent analysis (ELISA)] // Georgian Med News. — 2005. — № 124—125. — С. 65—7. — . ↑ Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome // Arch. Med. Res. : journal. — 2000. — Vol. 31, no. 2. — P. 216—222. — . ↑ [Evaluation of dopaminergic activity of the hypothalamus in patients with polycystic ovarian syndrome] // Minerva Ginecol. — 1991. — oktober (т. 43, № 10). — С. 443—447. — . ↑ Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012;28(7):509-15 (1997). Controlled trials of inositol in psychiatry. (2), 147-155. . (2001). Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. , (3), 335-339. (1995). Double-blind, controlled trial of inositol treatment of depression. , (5), 792-793. (2011). Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. , (1), 102-104. (2012). One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. , (5), 490-495. (1980). Myo-inositol content of common foods: development of a high-myo-inositol diet. (9), 1954-1967.